<DOC>
	<DOCNO>NCT02848651</DOCNO>
	<brief_summary>This Phase II , open-label , prospective , multicenter study design evaluate efficacy safety single-agent atezolizumab participant treatment-naive locally advanced metastatic NSCLC . In addition , primary biomarker objective evaluate various predictive cutoff novel blood-based diagnostic assay .</brief_summary>
	<brief_title>A Study Atezolizumab ( MPDL3280A ) First-line Monotherapy Advanced Metastatic Non-Small Cell Lung Cancer ( NSCLC ) : Clinical Evaluation Novel Blood-Based Diagnostics B-F1RST</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Histologically cytologically confirm Stage IIIBIVB NSCLC Measurable disease per RECIST v1.1 Adequate hematologic endorgan function Agreement remain abstinent ( refrain heterosexual intercourse ) use contraceptive method among woman childbearing potential Prior treatment immunotherapy chemotherapy stage NSCLC , include earlystage ( neoadjuvant adjuvant ) disease Participants epidermal growth factor receptor ( EGFR ) sensitize mutation anaplastic lymphoma kinase ( ALK ) rearrangement Active central nervous system ( CNS ) metastases require treatment Spinal cord compression definitively treat clinically stable Leptomeningeal disease Uncontrolled tumorrelated pain Uncontrolled pleural pericardial effusion ascites require recurrent drainage Uncontrolled symptomatic hypercalcemia Malignancies NSCLC within 5 year prior randomization , except curatively treat negligible risk metastasis death Pregnant lactate woman History autoimmune disease , significant pulmonary disease , significant cardiovascular disease Positive human immunodeficiency virus ( HIV ) hepatitis B C Active tuberculosis Severe infection major surgery within 4 week , antibiotic treatment acute infection within 2 week prior randomization Prior treatment hypersensitivity study drug relate compound Prior allogeneic bone marrow solid organ transplant Receipt live attenuate vaccine within 4 week prior randomization Treatment systemic immunomodulators within 4 week five halflives ( whichever short ) prior randomization Treatment systemic corticosteroid within 2 week prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>